Pharmacological modulators of autophagy activate a parallel noncanonical pathway driving unconventional LC3 lipidation.

Fiche publication

Date publication

mai 2017

Journal

Autophagy

Auteurs

Membres identifiés du Cancéropôle Est :
Dr JACQUIN Elise

Tous les auteurs :
Jacquin E, Leclerc-Mercier S, Judon C, Blanchard E, Fraitag S, Florey O

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28296541

Résumé

The modulation of canonical macroautophagy/autophagy for therapeutic benefit is an emerging strategy of medical and pharmaceutical interest. Many drugs act to inhibit autophagic flux by targeting lysosome function, while others were developed to activate the pathway. Here, we report the surprising finding that many therapeutically relevant autophagy modulators with lysosomotropic and ionophore properties, classified as inhibitors of canonical autophagy, are also capable of activating a parallel noncanonical autophagy pathway that drives MAP1LC3/LC3 lipidation on endolysosomal membranes. Further, we provide the first evidence supporting drug-induced noncanonical autophagy in vivo using the local anesthetic lidocaine and human skin biopsies. In addition, we find that several published inducers of autophagy and mitophagy are also potent activators of noncanonical autophagy. Together, our data raise important issues regarding the interpretation of LC3 lipidation data and the use of autophagy modulators, and highlight the need for a greater understanding of the functional consequences of noncanonical autophagy.